Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,662.00
(
0.26%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.33
(
-0.35%
)
Bitcoin
79,687.00
(
0.51%
)
News Focus
News Focus
Post# of 57920
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

food4thought

Send PM Follow Ignore
Followers 17
Posts 1798
Boards Moderated 0
Alias Born 10/11/2007

food4thought

Re: rusbrn post# 32443

Friday, 02/26/2010 2:45:40 PM

Friday, February 26, 2010 2:45:40 PM

Post# of 57920
Apparently APN01 is potentially a far better drug than CX-717. The argument that this indication is too difficult to create study now holds little water. Either poor marketing by Cor management or a poor molecule. You decide. With a potential $330 million payday, future trial design does not appear an issue, but clearly for Cor it's another phantom excuse. Not to mention the so called tightening of BP's partnering belt.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today